Why MannKind Stock Soared 19% Higher on Tuesday
Commercial-stage biotech MannKind (NASDAQ: MNKD) was a top choice of investors on the second day of the trading week. Tuesday saw MannKind's share price leap by almost 19%, making it stand out on a day when the S 500 index slumped by 0.4%.
The reason for the stock's jump wasn't hard to tease out.
MannKind, which concentrates on developing treatments for endocrine and lung disorders, published its second quarter results that day.
Source Fool.com
MannKind Corp. Aktie
5,50 €
1,38 %
Positive Tendenz für MannKind Corp. mit mehreren Buy- und keiner Sell-Einschätzung.
Ein Kursziel von 6 € für MannKind Corp. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 5.5 €.
